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Steroidogenic factor 1 (NR5A1, SF-1, Ad4BP) is a transcriptional regulator of
genes involved in adrenal and gonadal development and function. Mutations in
NR5A1 have been among the most frequently identified genetic causes of
gonadal development disorders and are associated with a wide phenotypic
spectrum. In 46,XY individuals, NR5A1-related phenotypes may range from
disorders of sex development (DSD) to oligo/azoospermia, and in 46,XX
individuals, from 46,XX ovotesticular and testicular DSD to primary ovarian
insufficiency (POI). The most common 46,XY phenotype is atypical or female
external genitalia with clitoromegaly, palpable gonads, and absence of M€ullerian
derivatives. Notably, an undervirilized external genitalia is frequently seen at
birth, while spontaneous virilization may occur later, at puberty. In 46,XX
individuals, NR5A1 mutations are a rare genetic cause of POI, manifesting as
primary or secondary amenorrhea, infertility, hypoestrogenism, and elevated
gonadotropin levels. Mothers and sisters of 46,XY DSD patients carrying
heterozygous NR5A1 mutations may develop POI, and therefore require
appropriate counseling. Moreover, the recurrent heterozygous p.Arg92Trp
NR5A1 mutation is associated with variable degrees of testis development in
46,XX patients. A clear genotype-phenotype correlation is not seen in patients
bearing NR5A1 mutations, suggesting that genetic modifiers, such as
pathogenic variants in other testis/ovarian-determining genes, may contribute to
the phenotypic expression. Here, we review the published literature on
NR5A1-related disease, and discuss our findings at a single tertiary center in
Brazil, including ten novel NR5A1 mutations identified in 46,XY DSD patients.
The ever-expanding phenotypic range associated with NR5A1 variants in XY and
XX individuals confirms its pivotal role in reproductive biology, and should alert
clinicians to the possibility of NR5A1 defects in a variety of phenotypes
presenting with gonadal dysfunction.
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Introduction
NR5A1 (nuclear receptor subfamily 5 group A, member 1),
previously known as SF1 (Steroidogenic Factor-1) and
Ad4BP (Adrenal 4-Binding Protein), was first cloned by
Parker and colleagues in 1992, in an attempt to identify a
protein that could activate the promoters of steroid
hydroxylase enzymes (Lala et al., 1992).
NR5A1 is expressed in steroidogenic tissues (Honda
et al., 1993; Ikeda et al., 1993; Morohashi et al., 1994; Par-
ker and Schimmer, 1997; Ramayya et al., 1997; Morohashi,
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1999), pituitary gonadotrophs (Barnhart and Mellon,
1994; Ingraham et al., 1994; Ngan et al., 1999), and neu-
rons located at the dorsomedial portion of the ventromedi-
al hypothalamus (VMH) (Ramayya et al., 1997; Morohashi
et al., 1999). In developing embryos, Nr5a1 is expressed in
the urogenital ridge, representing the first marker of
gonadal and adrenal differentiation (Ikeda et al., 1994;
Morohashi et al., 1995, 1999; Ramayya et al., 1997; Hanley
et al., 1999, 2001). Throughout human development,
NR5A1 is expressed in the steroid-secreting adrenal cor-
tex, in Leydig and Sertoli cells, as well as in granulosa and
theca cells.
NR5A1 stimulates the expression of several genes
required for the development and maintenance of the
male differentiation cascade. It regulates the expression of
LHCGR and the steroidogenic enzymes STAR, CYP11A1, and
CYP17A1 in Leydig cells, required for testosterone biosyn-
thesis. NR5A1 also increases the expression of insulin-like
polypeptide 3 (INSL3), which regulates testicular descent
and is a survival factor for male germ cells in adults (Zim-
mermann et al., 1998; Tremblay and Robert, 2005). Anti-
Mullerian hormone (AMH) and its receptor, AMHR2, essen-
tial factors for male reproductive tract development, are
also regulated by NR5A1. In Sertoli cells, NR5A1 regulates
the expression of the testis-determining genes SRY and
SOX9 (Jeyasuria et al., 2004).
Mutations in NR5A1 are emerging as a frequent genetic
cause of human 46,XY disorders of sex development
(DSD), having been identified throughout the globe. In
South America, familial and sporadic DSD patients bearing
NR5A1 defects have been described in Brazil and Argenti-
na (Lourenc¸o et al., 2009; Ciaccio et al., 2012; Gabriel
Ribeiro de Andrade et al., 2014; Fabbri et al., 2016). Here,
we review the phenotype associated with ten novel and
one previously described NR5A1 allelic variants identified
in a Brazilian cohort of 46,XY and 46,XX DSD patients fol-
lowed at a single tertiary center. Our findings are dis-
cussed in light of previously published reports, and
several aspects of the phenotypic spectrum associated
with NR5A1 mutations in humans are reviewed.
Patients
This is a retrospective study approved by the Ethics Com-
mittee of Hospital das Clinicas, University of Sao Paulo
Medical School. Written informed consents were obtained
from all patients or their parents/guardians.
The full cohort of DSD patients followed at the Devel-
opmental Endocrinology Unit at Hospital das Clinicas con-
sisted of 83 patients with 46,XY DSD (48 patients with
46,XY gonadal dysgenesis and 35 patients with 46,XY DSD
of unknown cause) and 90 patients with 46,XX DSD (70
patients with primary ovarian failure (44 patients had pri-
mary amenorrhea and 26 patients had secondary amenor-
rhea) and 20 patients with 46,XX SRY negative disorders
of ovary development (16 with 46,XX ovotesticular DSD
(OTDSD) and 4 with 46,XX testicular DSD (TDSD)).
Molecular Analysis
Mutational analysis of NR5A1 (Ensembl transcript
ESNT00000373588) was performed by Sanger sequencing
and by targeted massively parallel sequencing (TMPS), as
detailed in Supporting Information.
Identified allelic variants were analyzed according to
the joint American College of Medical Genetics and Geno-
mics Association for Molecular Pathology Guidelines
(Richards et al., 2015) (see Supporting Information)
IN SILICO ANALYSIS
Alignment of wild-type and mutated NR5A1 sequences
was performed using MUSCLE (Edgar, 2004) and the
NCBI’s Reference Sequence (RefSeq) database. To evaluate
the impact of NR5A1 nonsynonymous mutations at the
tertiary protein structure, several structural models were
built for wild-type and mutated molecules in the YASARA
suite (Krieger et al., 2004), using as templates the crystal
structures of the human liver receptor homologue 1 (LRH-
1, NR5A2) DNA-binding domain (DBD) in complex with
the hCYP7A1 promoter (PDB accession code 2A66), and
the human NR5A1 ligand-binding domain (LBD) in com-
plex with di-pamitoyl-3-SN-phosphatidylethanolamine
(PDB accession code 1ZDT). Stereo chemical quality of
generated structural models was accessed with MOLPRO-
BITY (Davis et al., 2007). Two molecular mechanics simu-
lations were carried in explicit solvent for each model.
Trajectories were calculated with the YAMBER3 force field.
Ten thousand simulation steps of 2.5 fs were recorded for
each wild type and its corresponding mutated molecules.
The final confirmation of the lowest energy models was
confirmed for each pair of simulations. The volumes of the
cavities of the models were calculated using KVFINDER
(Oliveira et al., 2014). Molecular models were drawn using
PyMOL (www.pymol.org).
IN VITRO FUNCTIONAL STUDIES
Transient gene expression assays were performed using
human embryonic kidney TSA-201 cells to analyze tran-
scriptional activation of murine Cyp11a1 and rat Cyp19
promoters by wild-type or mutant NR5A1 (Lin et al.,
2007) (see Supporting Information).
Results
We identified 11 pathogenic NR5A1 variants, including 10
novel variants in 46,XY DSD patients and one previously
reported variant in a 46,XX testicular DSD patient.
CLINICAL AND HORMONAL CHARACTERISTICS OF 46,XY DSD PATIENTS
BEARING PATHOGENIC NR5A1 VARIANTS
Nine of ten 46,XY DSD patients presented with atypical
genitalia at birth and one had female external genitalia.
Nine patients were assigned as female at birth, one of
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TABLE 1. Clinical Phenotype of Ten 46,XY DSD Patients and One 46,XX Testicular DSD Patient in Whom NR5A1 Mutations Were Identified
Patient Karyotype
Age at first
evaluation
(years) External genitalia
Mullerian
structures
Age at
surgery Sex of rearing Family
1 46,XY 0.5 Atypical
Phallus 3 cm, perineal
hypospadias, palpable
testes
A Genitoplasty at 1.6 years Male NA
2a 46,XY 0.7 Atypical
Clitoromegaly, palpable
gonads
A Gonadectomy at 9 ma;
Genitoplasty at
2 years
Female NA
3 46,XY 4.9 Atypical
Single perineal opening,
palpable gonads
A Gonadectomy and
Genitoplasty at
4.9 years
Female M – WT, F – NA
4a 46,XY 12 Atypical
Clitoromegaly
(2.0 cm),single perineal
opening, palpable
gonads
A Gonadectomy
at 3 years
Female NA
5 46,XY 12.3 Atypical
Clitoromegaly (4.0 cm),
two perineal openings,
no palpable gonads.
Virilization at puberty
A Gonadectomy and
Genitoplasty
at 12.5 years
Female Mother is a carrier
of the mutation
and presented
with POI
6 46,XY 13 Atypical
Clitoromegaly (3cm),
labial fusion, no palpa-
ble gonads
P Gonadectomy and
Genitoplasty at
15.5 years
Female Mother is a carrier
of the mutation,
F – NA
7a 46,XY 16.7 Atypical
Clitoromegaly, left
gonad palpable
P Gonadectomy at
14 years;
Genitoplasty
at 15 years
Female NA
8 46,XY 21 Female genitalia P Not performed Female NA
9a 46,XY 26 Atypical
Phallus 6.5 cm, perine-
al hypospadias, palpa-
ble testes
A Genitoplasty
at 26 years
Female to
Male (9 years)
NA
10a 46,XY 39 Atypical, clitoromegaly
(3cm), two perineal
opening
A Gonadectomy
at 14 years;
Genitoplasty
at 39 years
Female NA
11a 46,XX 59 Atypical, no palpable
gonads
A Genitoplasty
in childhood
Male NA
aSurgery performed previously to the evaluation in our center.
P, present; A, absent; F, father; M, mother; NA, not available; years, years of age; POI, primary ovarian insufficiency.
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whom reassigned to male at 9 years of age (patient 9,
Table 1); only one patient was assigned as male at birth
(patient 1, Table 1). The initial assessment at our specialist
unit ranged from 0.75 to 39 years of age. Only three
patients were seen in childhood, and the remaining after
puberty; four of these patients had previously undergone
bilateral gonadectomy. The patient with normal-appearing
female external genitalia was referred at 21 years of age
due to primary amenorrhea (patient 8, Table 1).
Basal hormonal evaluation was available for seven
patients. Gonadotropin levels were available in three
prepubertal and in four postpubertal patients. All postpu-
bertal patients had elevated gonadotropin levels, mainly
FSH. Among four postpubertal patients, basal testosterone
levels were normal for age in three (360, 155, and 414 ng/
dl, respectively) and low in the single patient with normal
female external genitalia (patient 8). A stimulation test with
hCG was performed in four patients (two prepubertal and
two pubertal) and in all of them testosterone levels
increased adequately (Table 2).
Seven patients underwent bilateral gonadectomy; age
at gonadectomy ranged from 9 months to 15.5 years. The
two patients who were raised as males had inguinal testes
and underwent bilateral orchiopexy. Gonadectomy was not
performed in one patient who discontinued follow-up
care. In three patients, a uterus was identified by pelvic
ultrasound or MRI (Table 1).
None of the patients had symptoms or signs of adrenal
insufficiency, and normal basal adrenal function was docu-
mented in six patients.
A family history of DSD was presented in three cases.
Patient 6 had two paternal cousins with atypical genitalia.
Patient 7 reported two second-degree cousins with primary
amenorrhea. Patient 5’s mother, who also carried the
NR5A1 variant, developed ovarian insufficiency at 39 years.
CLINICAL AND HORMONAL CHARACTERISTICS OF THE 46,XX DSD
PATIENT BEARING A PATHOGENIC NR5A1 VARIANT
Although mutations in NR5A1 have been reported in a
small proportion of women with primary ovarian insuffi-
ciency (POI), NR5A1 mutations were not identified in 70
patients with POI in our cohort. However, the previously
described p.Arg92Trp NR5A1 mutation was found in het-
erozygous state in one 46,XX patient with testicular DSD.
This patient (Patient 11, Table 1) was first seen in our
Unit when he was 59 years old. He was born with atypical
genitalia and had undergone masculinizing genitoplasty
during childhood. Spontaneous secondary sexual charac-
teristics such as phallic enlargement were absent and tes-
tosterone replacement was started at 15 years of age.
Bilateral mastectomy was performed at 18 years of age.
TABLE 2. Hormonal Profiles of Brazilian 46,XY DSD and 46,XX Testicular DSD
Patients in Whom NR5A1 Mutations Were Identified
Patient
Age
(years)
FSH
(U/l)
LH
(U/l)
Testosterone
(ng/dl)
Basal After hCG
1 0.5 NA NA 11 458
13 6 5 NA 508
2a 0.7 2 4 NA 12
3 4.9 5 <0.6 14 169
4a 12 NA NA NA NA
5 12.3 77 13 414 NA
6a 13 NA NA NA 277
7 13 69 24 155 295
8 21 60 16 14 NA
11a 26 21 14 360 499
9a 39 NA NA NA NA
10a 59 45 28 178 NA
Chronological age corresponding to the hormonal evaluation.
Conversion factors to SI units: T, ng/dl to nmol/l, multiply by 0.0347
aSurgery performed previously to the evaluation in our Center
NA, not available.
FIGURE 1. The ten novel mutations identified in 46,XY DSD patients and their localization on the NR5A1 protein. DBD, DNA-binding domain; LBD, ligand-binding
domain; AF2, activation function domain.
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He did not have symptoms or signs of adrenal insufficien-
cy, and basal adrenal profiling was normal. Peripheral
blood leukocyte DNA was PCR-analyzed for Y-specific
genes such as SRY, TSPY, AMGY, DYZ3, DYS280, and DYS1,
all of which were not amplified and therefore considered
absent. Pelvic MRI performed at 59 years of age revealed
small bilateral testes in the inguinal regions; a uterus was
not identified.
MOLECULAR CHARACTERISTICS OF NOVEL NR5A1 DEFECTS
Ten novel heterozygous NR5A1 mutations were identified in
46,XY DSD patients (Fig. 1), including five nonsynonymous
variants (p.Gly26Glu, p.Thr29Arg, p.Trp302Cys, p.Ala340Val,
p.Leu358Pro), four stop-gain variants (p.Tyr211*, p.Cys247*,
p.Tyr404*, p.Cys412*), and one frameshift variant (p.Glu395-
del) (Table 3, Fig. 1). In three cases DNA samples were
obtained from patients’ mothers; two of them carried NR5A1
mutations (Table 3).
The previously described common nonsynonymous
p.Gly146Ala variant (rs1110061) was identified in two
patients in association with p.Trp302Cys and p.Tyr404*
NR5A1 mutations, respectively.
IN SILICO STUDIES OF THE NR5A1 VARIANTS IDENTIFIED IN 46,XY
PATIENTS
Primary sequence analyses showed that all NR5A1 mutated
amino acids are extremely conserved among non-redundant
homologous and relative sequences. Regarding potential
and binding energies studies, native and mutated energy
distributions of the p.Gly26Glu, p.Trp302Cys, p.Leu358Pro,
p.Tyr404*, and p.Glu395del variants were compared. The
LBD domain mutations p.Trp302Cys and p.Tyr404* both led
to a higher energy state and therefore to a less stable mole-
cule in comparison with the wild-type protein (Fig. 2).
The p.Gly26Glu variant, located in the DBD, establishes
a polar contact not found in the original molecule, increas-
ing its affinity for DNA binding and making the NR5A1
dissociation from the DNA helix difficult, thus potentially
impairing transcriptional regulation. Interestingly, the
p.Gly26Glu variant seems to stabilize the DBD, leading to a
smaller energy compared to that of the native domain
(Fig. 2). As a consequence, an opposite behavior was
observed for binding energies. While all LBD mutated
molecules studied increased the bind energy to the ligand
di-pamitoyl-3-SN-phosphatidylethanolamine, p.Gly26Glu
provided smaller binding energy to the DNA helix.
Potential and binding energy means, variations, and over-
all conformations between mutated and native molecules
are shown in Table 4.
Figure 3 presents the lowest energy molecular models
of all mutated domains superposed to their respective
native versions. Replacement of Gly by Glu at position 26
creates an additional contact not present in the original
TABLE 3. Molecular Characterization of NR5A1 Defects Identified in Heterozygous State in Ten 46,XY and in One 46,XX Testicular DSD Patients
Patient
Mutation
(DNA)
Mutation
(protein) Domain Functional impact Bind energy
8 c.77G>A p.Gly26Glu DBD
(1st zinc finger)
In silico prediction: damaging #
9 c.86C>G p.Thr29Arg DBD In silico prediction:damaging NA
5 c.663C>G p.Tyr211* Hinge Truncated protein NA
2 c.741C>A p.Cys247* Hinge Truncated protein NA
7 c.906G>C
1c.437G>C
p.Trp302Cys
1p.Gly146Ala
LBD
Hinge
In silico prediction: damaging "
1 c. 1019C>T p.Ala340Val LBD In silico prediction: damaging NA
3 c.1073T>C p.Leu358Pro LBD Impaired transactivationfs a "
6 c.1183_1185del p.Glu395del LBD In silico prediction: damaging #
10 c.1212C>G
1c.437G>C
p.Tyr404*
1p.Gly146Ala
LBD
Hinge
Truncated protein "
11 c.1236C>A p.Cys412* LBD Truncated protein NA
4 c.274C>T p.Arg92Trp DBD
(A box)
Ref NA
The alignment of the rows is according to mutation location in the NR5A1protein. Binding energy to the “ligand di-pamitoyl-3-SN-
phosphatidylethanolamine of the mutated complex compared to the non-mutated complex.
Functional studies of mutated NR5A1 activity shown a reduction in the transcriptional activity of Cyp11a1 and Cyp19 promoters.
#, reduced bind energy; ", increased bind energy; DBD, DNA-binding domain; LBD, ligand-binding domain; NA, not available.
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DBD domain. The negatively charged Glu26 Oe2 forms a
salting bridge with the Arg79 Ne, which makes the
b-hairpin 21-20 less flexible and closer to the ligand DNA.
In the native LBD domain, the Try302imidazolic ring con-
tributes to form a hydrophobic environment of the active
site bottom cleft required to accommodate fatty ligands.
Removal of such a bulky amino acid at that position indu-
ces a whole structural reorganization so that the central
cavity of the protein shrinks, decreasing the occluded vol-
ume from 885 Å3 to 724 Å3. In turn, the p.Leu358Pro
mutation is located in a hydrophobic core surrounded by
four a-helices. In the original molecule, Leu358 establishes
several contacts with a network of hydrophobic residues.
Although proline is a non-polar amino acid, its side chain
is too small compared to leucine and cannot effectively
reach the surrounded hydrophobic residues. Therefore,
many hydrophobic contacts were lost, which may explain
the potential energy increasing. This change may be
responsible for the reduction of transcriptional activity
observed in the functional studies described below.
The variants p.Tyr211* and p.Cys247* are located in
hinge region of NR5A1 that is important for stabilizing the
LBD and interaction with other proteins that control
NR5A1 transcriptional activity.
Finally, the Glu385 deletion is located within LDB helix-
9, which is in the opposite direction of the ligand cleft.
Together with the N-terminal helix-1, these two external
helices tightly embrace the entire domain. In addition, the
removal of the Glu385 slightly rotates the helix-9 axial axis;
weakening several lateral contacts and making the helix
unroll half a turn. All these modifications are predicted to be
transmitted throughout the whole domain decreasing its
affinity to the ligand.
The results of the molecular simulation analyses
strongly support the hypothesis that all these novel muta-
tions potentially interfere with the activity of the NR5A1
protein. Its structural stability and its ability to bind the
di-palmitoyl-3-SN-phosphatidylethanolamine and probably
other fat can be affected by the presence of the mutations.
The function of such fat acid has not been cleared; howev-
er, it certainly provides additional contacts and stability to
the whole molecule to perform its activities. Altogether,
the simulation results strengthen the hypothesis that the
studied mutations are very likely deleterious.
IN VITRO FUNCTIONAL STUDIES OF THE P.LEU358PRO NR5A1 VARIANT
In vitro studies showed a markedly impaired transcrip-
tional activity of the p.Leu358Pro mutant NR5A1, with a
reduction of more than 70% and 80% in the transactiva-
tion of the Cyp11a1 and Cyp19 promoters, respectively
(Fig. 4).
Discussion
NR5A1 MUTATIONS IN 46,XY INDIVIDUALS
Since the first 46,XY DSD patient with the p.Gly35Glu
NR5A1 mutation described by Achermann et al. (1999),
the spectrum of phenotypes associated with NR5A1 muta-
tions has greatly expanded. This initial patient bearing the
FIGURE 2. (A) Energy distributions of the native NR5A1 LBD domain and
mutated molecules. A higher energy is associated with a less stable molecule
compared to the native due loss of amino acid contacts. (B) Energy distribu-
tions of the native NR5A1 DBD domain and its p.Gly26Glu mutated molecule.
A smaller energy is associated to a more stable molecule, compared to the
native due additional amino acids contacts.
TABLE 4. Variation of the Potential and Binding Energies Means Overall 9.000
Conformations Between Mutated and Native Molecules
Mutation/domain DE (kJ/mol) DEbind (kJ/mol)
p.Gly26Glu/DBD 3633 21746
p.Trp302Cys/LBD 9053 36
p.Leu358Pro/LBD 36,639 36
p.Glu395 del/LBD 11,656 59
All samples distributions passed Shapiro-Wilk normality test, being
means compared with Welsh’s t-test.
All resultant p values were less than 2.2 x 10216.
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heterozygous p.Gly35Glu mutation presented with adrenal
failure and gonadal dysgenesis with persistent Mullerian
derivatives (Woo et al., 2015), a phenotype that closely
resembled the phenotype observed in murine Nr5a1
knockout models (Luo et al., 1994). Gonadal dysgenesis
and adrenal insufficiency were also present in the second
reported NR5A1-related 46,XY DSD, in a patient bearing
the homozygous p.Arg92Gln mutation (Achermann et al.,
2002).
The expected phenotype associated with NR5A1 muta-
tions was shifted when a heterozygous 8-bp microdeletion
was found in a 46,XY DSD patient who presented with clito-
romegaly, absence of uterus and gonads but normal adrenal
function (Correa et al., 2004). After this first report, the
study of several cohorts of individuals with 46,XY DSD has
shown that adrenal insufficiency is a rare finding in patients
with NR5A1 defects (Lin et al., 2006; Guran et al., 2016).
Reported heterozygous NR5A1 mutations support the
model that partial NR5A1 dysfunction can result in several
degrees of impaired Leydig cell function and androgen bio-
synthesis, leading to predominantly abnormal gonadal
phenotypes, which can range from complete testicular dys-
genesis with Mullerian structures, through mild clitorome-
galy or atypical genitalia without Mullerian derivatives, to
proximal hypospadias associated with undescended testis
(K€ohler et al., 2009), or even micropenis with absent
gonads (Philibert et al., 2007).
Currently, NR5A1 mutations represent one of the most
frequent defects associated with 46,XY gonadal dysgenesis,
accounting for up to 20% of cases (Suntharalingham et al.,
2015).
More than 80 different NR5A1 variants, distributed
across the full length of the protein, have been described
and the majority are nonsynonymous mutations (Pedace
et al., 2014; Tantawy et al., 2014; Woo et al., 2015; Fabbri
et al., 2016). Most of these mutations are located in the
DBD and are in a heterozygous state or compound hetero-
zygous state with the p.Gly146Ala (rs1110061) variant,
FIGURE 3. Superimposed Models: Superimposition of the native (white) and mutated smallest energy NR5A1 models (colored): (A) DBD domain showing Glu26
and Arg79 salt bridge; (B) LBD domain showing Try302Cys; (C) LBD hydrophobic network with Leu358Pro in the center; and (D) LBD helix-9 rotated and
unrolled half a turn with the Glu385 deletion.
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with the exception of two mild mutations described in
homozygous state (Achermann et al., 2002; Soardi et al.,
2010). These findings reinforce the concept that NR5A1
dosage is critical to normal gonadal development. Howev-
er, a clear correlation between the location of a mutation,
its in vitro functional performance, and the associated phe-
notype is not observed. Indeed, family members bearing
the same NR5A1 mutation may present with variable phe-
notypes (Warman et al., 2011).
There are some hypotheses to explain the phenotypic
variation associated with a similar NR5A1 mutation. First,
interallelic association with the known p.Gly146Ala poly-
morphism (rs1110061) may further reduce NR5A1 activity
and contribute to more severe phenotypes (WuQiang
et al., 2003; Hasegawa et al., 2004; Wada et al., 2006; Reu-
ter et al., 2007; K€ohler et al., 2008; Lourenc¸o et al., 2009;
Bashamboo et al., 2010a; Paris et al., 2011; Camats et al.,
2012). However, two patients in our cohort also bore the
p.Gly146Ala variant besides the pathogenic NR5A1 var-
iants, p.Trp302Cys and p.Tyr404*, and their phenotype
was not strikingly distinct or more severe.
The contribution of other genetic modifiers has also
been suggested to explain phenotypic variability. Exome
sequencing analyses of DSD patients have identified patho-
genic variants or variants of uncertain significance in sev-
eral genes involved in sexual development (Bashamboo
et al., 2010b; Bashamboo et al., 2014). In a 46,XY patient
with atypical external genitalia, palpable inguinal gonads,
absent uterus in pelvic ultrasonography, and poor testos-
terone response to hCG stimulation, Mazen and colleagues
(2016) identified, by exome sequencing, the previously
described p.Arg313Cys NR5A1 mutation in compound het-
erozygous state with a p.Gln237Arg MAP3K1 variant. This
NR5A1 mutation was previously reported in association
with mild hypospadias (Allali et al., 2011), and a possible
digenic inheritance was proposed to explain the phenotyp-
ic heterogeneity (Mazen et al., 2016).
Progressive androgen production and virilization in
adolescence has been observed in several XY patients with
NR5A1 mutations, in contrast to the severe undervirilized
external genitalia found in most patients (Cools et al.,
2012; Gabriel Ribeiro de Andrade et al., 2014; Tantawy
et al., 2014; Fabbri et al., 2016). The almost normal testos-
terone levels after hCG stimulation or at pubertal age sug-
gest that NR5A1 action may be less implicated in pubertal
steroidogenesis than during fetal life. NR5A1 is expressed
in the both fetal and adult Leydig cells, but differences in
its actions at both stages are not completely known. The
study of a hypomorphic mouse model of Nr5a1 indicated
differential impairment of fetal and adult Leydig cell devel-
opment, whereby Nr5a1 may regulate the differentiation
of fetal Leydig cells, whereas in the adult it may regulate
progenitor cell formation and/or survival (Karpova et al.,
2015). Different actions of NR5A1 in fetal and postnatal
Leydig cells populations might contribute to the switch
from birth to pubertal phenotypes.
In contrast, fetal Sertoli cell function seems to be pre-
served in the most patients with heterozygous NR5A1
mutations, based on the common observation of absent
M€ullerian derivatives and primitive seminiferous tubules
on histology. In our cohort, three of 10 patients had
M€ullerian derivatives although in one of them the uterine
volume remained infantile after three years of estrogen
replacement.
The reviewed data of seventy-two 46,XY DSD patients
with NR5A1 mutations reported in the literature, for
whom information on presence or absence of M€ullerian
derivatives was available, suggested that M€ullerian deriva-
tives are present in about 24% of the cases (Pedace et al.,
2014; Tantawy et al., 2014; Woo et al., 2015; Fabbri et al.,
2016). However, persistently elevated FSH levels after
puberty found in all patients studied suggest an impair-
ment of Sertoli cells function in post pubertal age (Pedace
et al., 2014).
Male infertility has been also related to the presence of
NR5A1 defects (Bashamboo et al., 2010a; Ferlin et al.,
2015). Patients with moderate/severe oligospermia or azo-
ospermia and NR5A1 mutations may have normal testos-
terone and normal low or low inhibin B levels, but they
are at potential risk of deterioration of testicular hormonal
secretion with age and may need counseling regarding
FIGURE 4. Transcriptional activation of target gene promoters by wild-type
(WT) and mutant NR5A1 in human embryonic kidney TSA-201 cells. In vitro
activation of CYP11A1 and CYP19 gene promoters by the novel NR5A1
mutant p.Leu358Pro was reduced, in comparison to WT NR5A1 (29% and
18% of WT, respectively). Notably, the degree of transcriptional activity
impairment at the CYP11A1 promoter by p.Leu358Pro NR5A1 was compara-
ble to that of the well-known NR5A1 mutant p.Gly35Glu (Lin et al., 2007) and
more severe than p.Arg92Gln (Achermann et al., 2002). Results represent the
mean (SEM) for three assays, each performed in triplicate, and shown relative
to wild-type transactivation. RLU, relative luciferase units.
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preservation of sperm and regular monitoring of endo-
crine function (Bashamboo et al., 2010a).
The presence of ovotestis was described in a 46,XY
girl, with the 9q33.3-q34.1 deletion encompassing NR5A1
and LMX1B genes causing genitopatellar syndrome associ-
ated with female external genitalia and clitoromegaly
(Schlaubitz et al., 2007).
NR5A1 MUTATIONS IN 46,XX SUBJECTS
The first reported 46,XX patient with a NR5A1 mutation
(p.Arg255Leu) presented with isolated adrenal insufficiency,
but a follow-up description of ovarian function at postpuber-
tal age is lacking (Biason-Lauber and Schoenle, 2000). Subse-
quently, it was shown that NR5A1 mutations are also a
genetic cause of POI, with phenotypes ranging from primary
to secondary amenorrhea, associated with infertility, hypoes-
trogenism, and elevated gonadotropin levels (Lourenc¸o et al.,
2009; Camats et al., 2012) Sisters and mothers of 46,XY DSD
patients carrying heterozygous NR5A1 mutations may also
develop premature ovarian failure (Lourenc¸o et al., 2009;
Camats et al., 2012; Fabbri et al., 2016).
Several genes required for ovarian steroidogenesis, and
follicle growth and maturation are regulated by NR5A1,
explaining why mutant NR5A1 may lead to progressive loss
of ovarian function and female reproductive capacity
(Lourenc¸o et al., 2009; Camats et al., 2012; Fabbri et al.,
2016). Women bearing NR5A1 defects should receive appro-
priate counseling and fertility guidance, enabling potential
oocyte cryopreservation, due to the risk of developing ovari-
an insufficiency later in life.
In contrast to its prominent pathogenic role in 46,XY DSD,
NR5A1 defects are a rare cause of sporadic POI of unknown
etiology in women (1.4–1.6%). (Suntharalingham et al., 2015)
Sixteen different NR5A1 variants distributed across the full
length of the protein have been described in patients with
premature ovarian failure, and the majority of them are non-
synonymous mutations (Suntharalingham et al., 2015)
The spectrum of disorders associated with NR5A1 var-
iants in 46,XX individuals was further expanded by the
demonstration of the specific recurrent heterozygous
p.Arg92Trp NR5A1 variant, in association with variable
degrees of testis development in 46,XX patients from unre-
lated families (Baetens et al., 2016; Bashamboo et al.,
2016; Igarashi et al., 2017). The p.Arg92Trp NR5A1 muta-
tion was described in ten SRY negative 46,XX DSD patients,
six with testicular DSD and four with ovotesticular DSD.
This mutation was found in two familial cases: the first
one comprising two 46,XX ovotesticular DSD sisters and
the second one involving one 46,XX testicular DSD patient
and his 46,XY sister with partial gonadal dysgenesis. In
these two families a maternal inheritance was identified.
Atypical genitalia was the most frequent presentation (six
patients), but a phenotypic spectrum ranging from female
external genitalia with clitoromegaly (one patient), to male
external genitalia with micropenis (two patients) or
penoscrotal hypospadias (one patient) was observed.
Three of eight patients had a uterus, and two had a hemi-
uterus. Gonads were palpable in seven patients and the
other three 46,XX ovotesticular patients had bilateral
abdominal ovotestis.
The p.Arg92Gln NR5A1 mutation, located at the same
residue, was previously described in homozygous state in
a 46,XY phenotypic female with adrenal insufficiency and
in homozygous state in a 46,XX girl with early-onset pri-
mary adrenal insufficiency. This variant was also present,
in heterozygous state, in her phenotypically normal sister,
mother, and father. (Achermann et al., 2002; Guran et al.,
2016) Differences in the transactivating activity of the
p.Arg92Gln and the p.Arg92Trp mutants may be responsi-
ble for the significant phenotypic differences observed
(Igarashi et al., 2017) Nevertheless, the contribution of
modifying allelic variants in other genes involved in
gonadal development may not be completely excluded.
In vitro assays demonstrated that the p.Arg92Trp
mutant lost its binding capacity to a consensus NR5A1
response element and reduced activation of some minimal
promoters (Amh, Cyp11a1) (Bashamboo et al., 2016). This
mutated protein was also less sensitive to NR0B1-induced
suppression on the SOX9 TESCO element, leading to testis
formation (Igarashi et al., 2017). These findings suggest a
dysregulation of normal female gonadal development by
p.Arg92Trp NR5A1, tipping the balance toward testis
development in 46,XX individuals.
Conclusion
In a single-center Brazilian cohort, we have identified 10
novel NR5A1 mutations in 46,XY DSD patients and the pre-
viously described p.Arg92Trp mutation in one 46,XX testic-
ular DSD patient. Additionally, no mutations were found in
70 patients with POI. Our findings reinforce those of pre-
vious reports and contribute to expanding our understand-
ing of NR5A1-related phenotypes in humans.
NR5A1 mutations are associated with a wide spectrum
of disorders of gonadal development, ranging from DSD to
oligo/azoospermia in 46,XY individuals and 46,XX ovotes-
ticular and testicular phenotypes to primary ovarian fail-
ure in 46,XX individuals. The most frequent phenotype in
46,XY patients is atypical or female external genitalia with
clitoromegaly, palpable gonads, and absence of M€ullerian
derivatives. Postnatally, Leydig cells function seems to be
preserved in several patients with NR5A1 mutation, while
Sertoli and germ cells are more profoundly affected. The
severely undervirilized external genitalia frequently seen
at birth, contrasts with spontaneous virilization at puberty
in several patients. Phenotypic variability observed in
patients with similar NR5A1 defects may be related to the
association with genetic modifiers or pathogenic variants
in other testis/ovarian-determining genes.
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